SCHEMBL14427281

SCHEMBL14427281

CCOc1ccc(Oc2ccc(S(=O)(=O)N3CCc4ccccc4[C@@H]3C(=O)NO)cn2)cc1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MMP1 P03956 13/20 0.64
▸ MMP2 P08253 13/20 0.53
▸ MMP12 P39900 11/20 0.53
▸ MMP14 P50281 11/20 0.53
▸ MMP9 P14780 11/20 0.53
▸ MMP15 P51511 10/20 0.53
▸ MMP16 P51512 10/20 0.53
▸ MMP26 Q9NRE1 9/20 0.53
▸ MMP7 P09237 7/20 0.53
▸ MMP8 P22894 2/20 0.44
▸ MMP3 P08254 2/20 0.44
▸ HDAC1 Q13547 1/20 0.44
▸ HDAC2 Q92769 1/20 0.44
▸ HDAC8 Q9BY41 1/20 0.44
▸ MMP13 P45452 3/20 0.43
▸ ADAMTS4 O75173 1/20 0.43
▸ ADAMTS5 Q9UNA0 1/20 0.43
▸ ADAM17 P78536 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14427276 0.91 MMP1 (0.61) MMP1MMP2MMP12MMP14MMP9
SCHEMBL14427162 0.91 MMP1 (0.60) MMP1MMP2MMP12MMP14MMP9
SCHEMBL14427284 0.91 MMP1 (0.51) MMP1MMP2MMP12MMP14MMP9
SCHEMBL14427267 0.90 MMP1 (0.56) MMP1MMP2MMP12MMP14MMP9
SCHEMBL14427254 0.90 MMP1 (0.59) MMP1MMP2MMP12MMP14MMP9
SCHEMBL14427280 0.90 MMP1 (0.59) MMP1MMP2MMP12MMP14MMP9
SCHEMBL14427257 0.89 MMP1 (0.61) MMP1MMP2MMP12MMP14MMP9
SCHEMBL14427261 0.89 MMP1 (0.58) MMP1MMP2MMP12MMP14MMP9
SCHEMBL14427265 0.88 MMP1 (0.57) MMP1MMP2MMP12MMP14MMP9
SCHEMBL5445428 0.88 MMP1 (0.57) MMP1MMP2MMP12MMP14MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-30 — — US disclosed
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203118-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES USED IN THE FORM OF MMP INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS MMP9, MMP2, MMP3 MMP1 8/4885MMP2 2/4885MMP12 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback